Drug Trial Radar · NCT07744113
An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Alkermes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 10 years, up to 17 years
Summary
As written by the sponsor on the registry.
To provide continued access to OLZ/SAM for pediatric participants with schizophrenia or bipolar I disorder who have completed participation in the ALKS 3831-A313 long-term safety extension study.
Conditions
- Bipolar 1 Disorder
- Schizophrenia Disorder
Interventions
OLZ/SAMDrug
OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day , 5 mg/day, or 15mg/ day with a maximum daily dose of 20mg/day. The dose of samidorphan will be 10 mg/day.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alkermes Investigator Site
Miami, Florida · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.